Navigation Links
Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
Date:9/5/2012

SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR).  Enrollment into the study has continued without abatement at a rate faster than originally expected, with more than 4,500 patients enrolled as of August 31.  Orexigen now expects to close enrollment to new patients in the fourth quarter of 2012.

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After at least 87 MACE have been adjudicated, the study's independent Data Monitoring Committee will conduct an interim analysis. If the interim analysis excludes a doubling of risk of MACE in patients receiving Contrave compared to placebo, Orexigen plans to resubmit the Contrave New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for approval. The exclusion of a doubling of risk of MACE was established as the threshold for approvability of Contrave during discussions with the FDA prior to the start of the Light Study.

"By successfully expediting patient enrollment into the Light Study, we are executing on our promise to shareholders to do what we can to pull forward the time to the interim analysis," said Michael Narachi, CEO of Orexigen.

"The other key information needed to determine the timing of the interim analysis is the rate of MACE in the study, which is still too early to know," Narachi continued.  "Importantly, because the demographics of the patient population entering the study are in line with our targets for age, gender, race, smoking status, prevalence of cardiovascular disease and other co-morbid
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
3. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
6. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
7. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
10. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
11. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... products, today announced that it has entered into new ... in-center products to DaVita, the kidney care division of ... ) For the use of products for ... , NxStage has executed a second amended and restated ...
(Date:5/21/2013)... New data released today at the ... that the NeuroStar TMS Therapy System ® ... in patients with Major Depressive Disorder (MDD) during ... through one year of treatment.  At the end ... symptomatic improvement while 41 percent reported complete remission. ...
(Date:5/21/2013)... Quebec , May 21, 2013 ... (NYSE: VRX ) (TSX: ... ten directors nominated at its 2013 ... detailed results of the vote for ... out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2
... Astellas Pharma US, Inc. ("Astellas") recently hired Mark ... oncology. Reporting directly to Patrick Shea, senior vice ... responsible for all U.S. commercial activities supporting marketed ... lead commercial planning for early stage development compounds. ...
... The Targetech Innovation Center, supported by a strategic ... developing pipeline of biomedical device opportunities poised to begin ... "This is an exciting development in the strategic ... effort, we will see more companies locating to Akron. ...
Cached Medicine Technology:Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 3
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Modern ... the help of Texas Counseling’s Sexuality and Relationship ... and the development of healthier habits for their ... available for both couples and individuals at Texas ... their relationships and learn skills to develop long ...
(Date:5/21/2013)... Repository (DoDSR), University of Cincinnati (UC) researchers have identified ... which could help with earlier diagnosis and intervention in ... finding, the first of its kind and led by ... presentation by staff from Walter Reed National Military Medical ... 18-21 in Orlando, Fla. , The DoDSR is ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... A new study appearing in the ... stem cells harvested from fat (adipose) are more potent ... modulate the body’s immune system. , The finding ... as adipose tissue-derived stem cells (AT-SCs) are far more ... marrow and can be collected from waste material from ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... fears associated ... with common diabetes complication, ALEXANDRIA, Va., Oct. 4 ... ghosts and,goblins. But for some, there is something that is ... is a diabetes complication for both men and women.,According to ...
... N.J., Oct. 4 The National Confectioner,s,Association has ... go trick-or-treating,this year. With this in mind, Halloween ... brushing habits to their children. "Since candy ... eating on Halloween. Kids can enjoy chocolate and,lollipops ...
... benefit management ... organizations, ST. ... pharmacy benefit management, announced today it has,achieved URAC Pharmacy Benefit Management ... encourage PBM,industry best practices, promote quality improvement and protect and,empower consumers. ...
... 3 The following is a,statement by Michael Bender, ... credit, the US Food and Drug Administration and its ... a considerable,number of years to present a balanced and ... They recognized that there is,there is enough mercury in ...
... 3 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will be presenting at the 2007 BIO InvestorForum ... at the Palace Hotel in San,Francisco, California. Mr. ... http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will ...
... be allergic to,work? If you experience symptoms of allergies ... asthma. This disorder is defined as,reversible airflow obstruction caused ... harmful substances while "on the,job," according to the American ... that about 15%, or 1 in 7, of adult ...
Cached Medicine News:Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:Prime Therapeutics Announces URAC Accreditation 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 3Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
MT-BT-5011-25 Prostate seeding needle (set of 25 unloaded needles).,MT-BT-5011-P Prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seedin...
... offers five classes of resectoscope electrodes ... loops, knife, roller bar & ball, ... only electrodes specifically integrated into the ... removal with minimal bleeding, increased visibility, ...
... and MRO™-2005 Rigid Percutaneous Nephroscopes combine ... throughput capacity with proven MRO performance. ... with small size sheaths. The MRO™-20 ... easy positioning during percutaneous procedures. The ...
... Resectoscope is based on the award winning ... the surgeon to perform TURis - resection ... element, HF cable and electrodes, Olympus OES ... in saline, supporting both, standard TUR and ...
Medicine Products: